When stratifying the cohort by disease duration (< 50 months vs. ≥ 50 months), drug treatments, or clinical DM subtypes (amyopathic vs classic DM), we did not observe significant differences in IFNβ responses to lenabasum within these subgroups. Here, IFNB1 is linked to dermatomyositis.